Cytomegalovirus Infections Clinical Trial
To investigate the relationship between HCMV and bone marrow progenitor cells to understand whether HCMV is latent in CD34 + bone marrow progenitors and the mechanism by which the virus remains in a latent state.
BACKGROUND:
Despite progress in understanding the pathophysiology of human cytomegalovirus (HCMV)
infections, its manifestations in the immune compromised host are frequently associated with
high morbidity and mortality. In this setting, HCMV disease can develop e.g. following
immune suppression as a result of reactivation of latent HCMV acquired earlier in life. The
mechanisms leading to establishment of latent infections and their subsequent reactivation
are not clear. It is also unknown whether HCMV exists in a latent form with limited viral
gene expression or as a persistent infection with normal virus transcription.
DESIGN NARRATIVE:
The specific aims of the study were to: 1) examine the percentage of HCMV positive donors
whose bone marrow progenitors contained HCMV DNA using nested PCR and determine if virus
could be rescued from those cells. 2) Analyze the HCMV life cycle in hematopoietic
progenitor and stem cells. 3) identify and analyze HCMV gene expression in in vivo infected
leukocytes. Bone marrow progenitors containing HCMV DNA detectable by nested PCR were
isolated from human donors and used as as source of mRNA to prepare Cdna libraries. 4)
Determine if gene(s) expressed in bone marrow progenitors were important in either
establishing or maintaining a latent infection or in the lytic cycle of HCMV. Information
provided from the above studies yielded information important in planning future approaches
for the therapy of HCMV infections.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03950414 -
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
|
Phase 1 | |
| Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
| Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
| Recruiting |
NCT02671318 -
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
|
Phase 4 | |
| Completed |
NCT01325636 -
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00228202 -
Genotyping of Cytomegalovirus From Patients in Israel
|
N/A | |
| Completed |
NCT00031421 -
Neonatal CMV-Ganciclovir Follow-up Study
|
N/A | |
| Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
| Terminated |
NCT03262194 -
Relevance of Gastric Aspirate in HCMV Detection
|
||
| Completed |
NCT04478474 -
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
|
||
| Recruiting |
NCT05370976 -
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
|
Phase 2 | |
| Active, not recruiting |
NCT02943057 -
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
|
Phase 4 | |
| Completed |
NCT02538172 -
Cell-mediated Immunity for Prevention of CMV Disease
|
N/A | |
| Completed |
NCT02642822 -
The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University
|
N/A | |
| Completed |
NCT02134184 -
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
|
Phase 4 | |
| Completed |
NCT00673868 -
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
|
Phase 1 | |
| Active, not recruiting |
NCT05089630 -
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
| Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01986010 -
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
|
Phase 1 |